Ultragenyx Pharmaceutical (RARE) Reaches New 52-Week Low at $43.83
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)’s share price hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $43.83 and last traded at $45.24, with a volume of 405800 shares changing hands. The stock had previously closed at $45.57.
RARE has been the topic of several research reports. Evercore ISI initiated coverage on Ultragenyx Pharmaceutical in a research note on Wednesday, August 16th. They set an “in-line” rating and a $63.00 price target on the stock. SunTrust Banks lowered Ultragenyx Pharmaceutical from a “buy” rating to a “hold” rating and cut their price target for the company from $105.00 to $55.00 in a research note on Wednesday, August 23rd. Canaccord Genuity reaffirmed a “buy” rating and set a $83.00 price target (down previously from $98.00) on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, August 22nd. Cowen reaffirmed an “outperform” rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, August 23rd. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $83.00 price target (down previously from $89.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, August 23rd. One analyst has rated the stock with a sell rating, nine have given a hold rating and ten have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $72.40.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) EPS for the quarter, meeting analysts’ consensus estimates of ($1.87). The company had revenue of $0.20 million during the quarter, compared to the consensus estimate of $0.02 million. The company’s revenue for the quarter was up 81.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.64) EPS. research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -7.27 EPS for the current year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Sei Investments Co. bought a new stake in Ultragenyx Pharmaceutical in the second quarter valued at about $125,000. SG Americas Securities LLC bought a new stake in Ultragenyx Pharmaceutical in the third quarter valued at about $156,000. Tocqueville Asset Management L.P. increased its holdings in Ultragenyx Pharmaceutical by 8.0% in the second quarter. Tocqueville Asset Management L.P. now owns 3,375 shares of the biopharmaceutical company’s stock valued at $210,000 after purchasing an additional 250 shares during the last quarter. Pacer Advisors Inc. increased its holdings in Ultragenyx Pharmaceutical by 12.0% in the second quarter. Pacer Advisors Inc. now owns 3,402 shares of the biopharmaceutical company’s stock valued at $211,000 after purchasing an additional 365 shares during the last quarter. Finally, Kazazian Asset Management LLC bought a new stake in shares of Ultragenyx Pharmaceutical in the second quarter worth about $213,000. Institutional investors and hedge funds own 94.13% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Ultragenyx Pharmaceutical (RARE) Reaches New 52-Week Low at $43.83” was reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.watchlistnews.com/ultragenyx-pharmaceutical-rare-reaches-new-52-week-low-at-43-83/1762969.html.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with Analyst Ratings Network's FREE daily email newsletter.